JP2020502135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502135A5 JP2020502135A5 JP2019531812A JP2019531812A JP2020502135A5 JP 2020502135 A5 JP2020502135 A5 JP 2020502135A5 JP 2019531812 A JP2019531812 A JP 2019531812A JP 2019531812 A JP2019531812 A JP 2019531812A JP 2020502135 A5 JP2020502135 A5 JP 2020502135A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- plasminogen
- composition according
- drug
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 102000013566 Plasminogen Human genes 0.000 claims 10
- 108010051456 Plasminogen Proteins 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 210000005084 renal tissue Anatomy 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 5
- 230000000451 tissue damage Effects 0.000 claims 4
- 231100000827 tissue damage Toxicity 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 239000002220 antihypertensive agent Substances 0.000 claims 3
- 229940127088 antihypertensive drug Drugs 0.000 claims 3
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 230000003907 kidney function Effects 0.000 claims 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims 1
- 201000003126 Anuria Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000012639 Balance disease Diseases 0.000 claims 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010030302 Oliguria Diseases 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 206010037597 Pyelonephritis acute Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038540 Renal tubular necrosis Diseases 0.000 claims 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 201000001555 acute pyelonephritis Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 229940121357 antivirals Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 208000006750 hematuria Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000001524 infective effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 108010049112 miniplasminogen Proteins 0.000 claims 1
- 230000003589 nefrotoxic effect Effects 0.000 claims 1
- 231100000381 nephrotoxic Toxicity 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000011251 protective drug Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 229940034208 thyroxine Drugs 0.000 claims 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016110174 | 2016-12-15 | ||
| CNPCT/CN2016/110174 | 2016-12-15 | ||
| CN2016110169 | 2016-12-15 | ||
| CNPCT/CN2016/110169 | 2016-12-15 | ||
| PCT/CN2017/089059 WO2018107699A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗药物性肾损伤的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502135A JP2020502135A (ja) | 2020-01-23 |
| JP2020502135A5 true JP2020502135A5 (enExample) | 2020-07-30 |
| JP7242057B2 JP7242057B2 (ja) | 2023-03-20 |
Family
ID=62557856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531809A Active JP7182793B2 (ja) | 2016-12-15 | 2017-06-19 | 病理学的腎組織損傷を予防及び治療するための方法 |
| JP2019531812A Active JP7242057B2 (ja) | 2016-12-15 | 2017-06-19 | 薬物性腎損傷を予防及び治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531809A Active JP7182793B2 (ja) | 2016-12-15 | 2017-06-19 | 病理学的腎組織損傷を予防及び治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190328848A1 (enExample) |
| EP (2) | EP3556386A4 (enExample) |
| JP (2) | JP7182793B2 (enExample) |
| CN (2) | CN110366427A (enExample) |
| CA (2) | CA3047171A1 (enExample) |
| TW (4) | TW202123962A (enExample) |
| WO (3) | WO2018107700A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110114080A (zh) | 2016-12-15 | 2019-08-09 | 泰伦基国际有限公司 | 一种预防和治疗皮肤纤维化的方法 |
| TWI714862B (zh) | 2017-06-19 | 2021-01-01 | 大陸商深圳瑞健生命科學硏究院有限公司 | 一種調控glp-1/glp-1r的方法和藥物 |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CN113456579B (zh) * | 2021-07-12 | 2023-04-25 | 南开大学 | 具有双靶点的hdac抑制剂的纳米胶束-水凝胶制剂在治疗急性肾损伤药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| CN87104683A (zh) * | 1986-05-15 | 1988-12-21 | 埃默里大学 | 改善血纤维蛋白溶解作用的组合物 |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| EP1472346A2 (de) * | 2002-02-06 | 2004-11-03 | N-Zyme BioTec GmbH | Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen |
| JP2006507297A (ja) * | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| ATE331708T1 (de) * | 2002-12-10 | 2006-07-15 | Wyeth Corp | Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren |
| US20050250694A1 (en) * | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| CA2577782A1 (en) * | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as pai-1 inhibitors |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| EP2056864B1 (en) * | 2006-08-28 | 2013-12-11 | Omnio Healer AB | Candidates against infection |
| CA2763496A1 (en) * | 2009-05-26 | 2010-12-02 | Yaremi Quiros Luis | Urinary gm2 activator protein as a marker of acute renal failure or the risk of developing acute renal failure |
| EP2451835A1 (en) * | 2009-07-10 | 2012-05-16 | ThromboGenics N.V. | Variants of plasminogen and plasmin |
| CN102121023B (zh) * | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| ES2583082T3 (es) * | 2011-01-05 | 2016-09-19 | Thrombogenics N.V. | Variantes de plasminógeno y plasmina |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| CN107496899A (zh) * | 2011-09-29 | 2017-12-22 | 梅约医学教育与研究基金会 | 芳族阳离子肽和使用它们的方法 |
| US9845363B2 (en) * | 2013-08-13 | 2017-12-19 | Sanofi | Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof |
| JP6512213B2 (ja) * | 2014-02-21 | 2019-05-15 | アステラス製薬株式会社 | 新規抗ヒトｐａｉ−１抗体 |
-
2017
- 2017-06-19 JP JP2019531809A patent/JP7182793B2/ja active Active
- 2017-06-19 EP EP17880935.6A patent/EP3556386A4/en active Pending
- 2017-06-19 CN CN201780078167.1A patent/CN110366427A/zh active Pending
- 2017-06-19 TW TW110102361A patent/TW202123962A/zh unknown
- 2017-06-19 CN CN201780078117.3A patent/CN110167582A/zh active Pending
- 2017-06-19 JP JP2019531812A patent/JP7242057B2/ja active Active
- 2017-06-19 EP EP17881449.7A patent/EP3556388A4/en active Pending
- 2017-06-19 CA CA3047171A patent/CA3047171A1/en not_active Abandoned
- 2017-06-19 TW TW106120455A patent/TW201822797A/zh unknown
- 2017-06-19 US US16/469,960 patent/US20190328848A1/en not_active Abandoned
- 2017-06-19 CA CA3047170A patent/CA3047170A1/en not_active Abandoned
- 2017-06-19 US US16/469,991 patent/US20190343930A1/en not_active Abandoned
- 2017-06-19 WO PCT/CN2017/089060 patent/WO2018107700A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089059 patent/WO2018107699A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089055 patent/WO2018107695A1/zh not_active Ceased
- 2017-06-20 TW TW106120523A patent/TWI661838B/zh active
- 2017-06-20 TW TW106120521A patent/TWI642441B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502135A5 (enExample) | ||
| Yu et al. | Expert consensus on the use of human serum albumin in critically ill patients | |
| Priante et al. | Cell death in the kidney | |
| Pitt et al. | Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors | |
| Finley | Drug interactions with lithium: an update | |
| JP2020511416A5 (enExample) | ||
| Hanafusa | Application of continuous renal replacement therapy: what should we consider based on existing evidence? | |
| McCullough et al. | Use of oral anticoagulation in the management of atrial fibrillation in patients with ESRD: pro | |
| Iqbal et al. | Diuretic resistance and its management | |
| JP2020502134A5 (enExample) | ||
| JP2020502155A5 (enExample) | ||
| Jacomella et al. | Novel anticoagulants in the therapy of peripheral arterial and coronary artery disease | |
| Baldwin et al. | Treatment of hypertension in renal disease | |
| CN110167582A (zh) | 一种预防和治疗药物性肾损伤的方法 | |
| Palmer et al. | Renal considerations in the treatment of hypertension | |
| Biancofiore et al. | Intravenous fenoldopam for early acute kidney injury after liver transplantation | |
| Ohya et al. | A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients | |
| Singh et al. | Effects of Salacia oblonga on cardiovascular risk factors in chronic kidney disease patients: a prospective study | |
| Haller et al. | Platelet activation in patients with atherosclerotic renal artery stenosis undergoing stent revascularization | |
| Sever et al. | CD2AP, dendrin, and cathepsin L in the kidney | |
| Rosner et al. | Drug-associated acute kidney injury in the intensive care unit | |
| Suliman et al. | Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients | |
| Shringi et al. | The cardiovascular unphysiology of thrice weekly hemodialysis | |
| Pourreau et al. | Bilateral renal cortical necrosis with end-stage renal failure following envenoming by Proatheris superciliaris: A case report | |
| Ananthakrishnan et al. | Nephrotic Syndrome |